Explore by Category
Oncopeptides Launches Expanded Access Melflufen Program for Multiple Myeloma Patients
MYELOMA NEWS - October 01, 2020
Oncopeptides has launched their United States Expanded Access Program with melflufen (also called Melphalan Flufenamide) for relapsed or refractory patients who... Read More
Tandem Transplants vs. Auto-Allo Transplants in Multiple Myeloma
MYELOMA NEWS - September 30, 2020
Which is better, two back-to-back autologous stem cell transplants or one auto followed by one allo (donor) transplant? Myeloma researcher Luciano Costa, M... Read More
FDA Grants Priority Review for Ide-Cel CAR T Therapy
MYELOMA NEWS - September 28, 2020
In a recent press release, Bristol Myers Squibb and bluebird bio announced that the FDA has accepted the new drug application for ide-cel (idecabtagene vicleuce... Read More
FDA Grants Orphan Drug Status to New CD38 Antibody Redirecting Molecule (ARM) Myeloma Therapy
MYELOMA NEWS - September 18, 2020
The FDA has granted Orphan Drug designation to a new type of myeloma therapy called an Antibody Redirecting Molecule (ARM) targeting CD38. The orphan drug ... Read More
MRD Negativity is Better than Stringent Complete Response (sCR) to Determine Myeloma Patient Outcomes
MYELOMA NEWS - September 17, 2020
In a head-to-head study comparing minimal residual disease (MRD) testing vs. using the "stringent complete response" measurement, MRD indicated a more... Read More
New Ways to Use Our Own T Cells to Treat Myeloma
MYELOMA NEWS - September 14, 2020
Most of us have been reading about CAR-T treatments over the past few years to treat a variety of hematological malignancies. Two CAR-T products have been on th... Read More
Ninlaro with Dex and Revlimid Extends Survival for Newly Diagnosed, Transplant Ineligible Myeloma Patients
MYELOMA NEWS - September 11, 2020
New study results showed that the triplet combination including Ninlaro, lenalidomide and dex increased progression free survival for newly diagnosed myeloma pa... Read More
More Good News for Newly Diagnosed, High Risk Myeloma Patients
MYELOMA NEWS - September 11, 2020
Unfortunately, some of us are or have been tagged as high-risk myeloma patients (and I am one of them). There is some good news that has been reported from Germ... Read More
New Rules for the Centers for Medicare and Medicaid Services on CAR T Therapy
MYELOMA NEWS - September 04, 2020
The Centers for Medicare and Medicaid Services (CMS) recently approved new rules for the use of CAR T treatment for Medicare and Medicaid payment... Read More
Expanded Access in the United States: What Does It Mean & Its Role In Future Drug Development
MYELOMA NEWS - September 01, 2020
Jess Rabourn of Ax-S Pharma, LLC provides an overview on the principles and practices of Expanded Access programs Patients are frustrated. And their doctor... Read More
The Best Dose of Lenalidomide as Maintenance Therapy in Multiple Myeloma
MYELOMA NEWS - August 24, 2020
In the first study of high dose vs. low dose lenalidomide maintenance, German researchers found that a 10-15mg dose of lenalidomide was most effective in e... Read More
FDA Clears New Use of Kyprolis with Daratumuamb and Dex for Relapsed Multiple Myeloma Patients
MYELOMA NEWS - August 20, 2020
Today the FDA approved the use of Kyprolis (carfilzomib) in a new combination with DARZALEX (daratumumab) and dexamethasone (also called DKd). The approval cove... Read More
How IVig Boosts the Immune System and Kills Multiple Myeloma
MYELOMA NEWS - August 19, 2020
Myeloma patients can often have low levels of normal antibodies that fight infection. Those low levels can lead to issues with recurring infections. If antibody... Read More
